Erratum: Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy (PLoS ONE (2014) 9:1 (e84940) doi:10.1371/journal.pone.0084940);Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  De Re, Valli ^a   Caggiari, Laura ^a   De Zorzi, Mariangela ^a   Talamini, Renato ^a   Racanelli, Vito ^b   D'Andrea, Mario ^c   Buonadonna, Angela ^a   Zagonel, Vittorina ^d   Cecchin, Erika ^a   Innocenti, Federico ^e   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c SAN FILIPPO NERI HOSPITAL   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; HLA ANTIGEN; IRINOTECAN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; KIR GENE; KIR2DL5A GENE; KIR2DS1 GENE; KIR2DS5 GENE; KIR3DS1 GENE; MALE; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; TREATMENT RESPONSE; TUMOR GROWTH;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HLA ANTIGENS; HLA-B ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; RECEPTORS, KIR; RECEPTORS, KIR3DL1; TREATMENT OUTCOME;

EID: 84897510473     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092487     Document Type: Erratum

References (74)

1. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, et al. (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14: 29-37.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, et al. (2011) Irinotecan combined with fluorouracil comparedwith fluorouracil alone as firstline treatment formetastatic colorectal cancer: A multicentre randomized trial. Lancet 355,1041-1047.
3. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, et al. (2013) Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19: 462-468.
4. Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, et al. (2013) Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value. PLoS Medicine 10.
5. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412-7420.
6. Ciombor KK, Berlin J, Chan E (2013) Aflibercept. Clin Cancer Res 19: 1920- 1925.
7. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, et al. (2013) PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer. Clin Cancer Res 19: 3285- 3296.
8. Deschoolmeester V, Baay M, Lardon F, Pauwels P, Peeters M (2011) Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI. Cancer Microenviron 4: 377-392.
9. Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, et al. (2009) Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 69: 2685-2693.
10. Xu Y, Xu Q, Ni S, Liu F, Cai G, et al. (2011) Decrease in natural killer cell associated gene expression as a major characteristic of the immune status in the bloodstream of colorectal cancer patients. Cancer Biol Ther 11: 188-195.
11. Halama N, Braun M, Kahlert C, Spille A, Quack C, et al. (2011) Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 17: 678-689.
12. Bossard C, Bezieau S, Matysiak-Budnik T, Volteau C, Laboisse CL, et al. (2011) HLA-E/beta2 microglobulin over-expression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int J Cancer: 10.
13. Paust S, Senman B, von Andrian UH (2010) Adaptive immune responses mediated by natural killer cells. Immunol Rev 235: 286-296.
14. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, et al. (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
15. Carrington M, Martin MP (2006) The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol 298: 225-57.
16. Beziat V, Descours B Parizot C Debre P Vieillard V (2010) NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One 5: e11966.
17. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, et al. (2006) Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med %20;203: 633-645.
18. Gourraud PA, Meenagh A, Cambon-Thomsen A, Middleton D (2010) Linkage disequilibrium organization of the human KIR superlocus: implications for KIR data analyses. Immunogenetics 62: 729-740.
19. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L (2008) Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 9: 486-494. (Pubitemid 351560517)
20. Nagasaki E, Takahara A, Koido S, Sagawa Y, Aiba K, et al. (2010) Combined treatment with dendritic cells and 5-fluorouracil elicits augmented NK cellmediated antitumor activity through the tumor necrosis factor-alpha pathway. J Immunother 33: 467-474.
21. Chen LL, Chen X, Choi H, Sang H, Chen LC, et al. (2012) Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother 6: 1113-1124.
22. Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, et al. (2005) Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol 175: 820-828. (Pubitemid 41094964)
23. De Re V, Caggiari L, De Zorzi M, Toffoli G (2011) Kir Molecules: Recent Patents of Interest for the Diagnosis and Treatment of Several Autoimmune Diseases, Chronic Inflammation, and b-Cell Malignancies. Recent Pat DNA Gene Seq 5: 169-174.
24. Mocikat R, Braumuller H, Gumy A, Egeter O, Ziegler H, et al. (2003) Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19: 561-569. (Pubitemid 37311437)
25. Signorino E, Brusa D, Granata R, Malavasi F, Ferrone S, et al. (2007) Contribution of dendritic cells' FcgammaRI and FcgammaRIII to crosspresentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies. Cancer Biol Ther 6: 1932-1937. (Pubitemid 351590406)
26. Mantovani A, Romero P, Palucka AK, Marincola FM (2008) Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371: 771-783.
27. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, et al. (2006) The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24: 3061-3068.
28. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization.
29. Caggiari L, Toffoli G, De Re V, Orzes N, Spina M, et al. (2011) KIR/HLA combination associated with the risk of complications in celiac disease. Int J Biol Markers 26: 221-228.
30. Caggiari L, Cannizzaro R, De Zorzi M, Canzonieri V, Da Ponte A, et al. (2008) New HLA-A*680106 allele identified in individuals with celiac disease from the Friuli area of northeast Italy. Tissue Antigens 72: 491-92.
31. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 39: D913-D919.
32. Pyo CW, Guethlein LA, Vu Q, Wang R, Abi-Rached L, et al. (2010) Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. PLoS One 5: e15115.
33. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, et al. (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7: 753- 763.
34. Carrington M, Norman P (2003) The KIR Gene Cluster. Bethesda (MD): National Center for Biotechnology Information (US); Available: http://www. ncbi.nlm.nih.gov/books/NBK10134/. Accessed 2010 October 4.
35. Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, et al. (2007) Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 178: 33-37. (Pubitemid 46033585)
36. Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, et al. (2010) Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Human Immunology 71: 976-981.
37. Middleton D, Vilchez JR, Cabrera T, Meenagh A, Williams F, et al. (2007) Analysis of KIR gene frequencies in HLA class I characterised bladder, colorectal and laryngeal tumours. Tissue Antigens 69: 220-226. (Pubitemid 46696942)
38. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, et al. (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-66.
39. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, et al. (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin k C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18: 2695-703.
40. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134-144.
41. Benson DM, Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, et al. (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116: 2286-2294.
42. Seidel UJ, Schlegel P, Lang P (2013) Natural killer cell mediated antibodydependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 4: 76. doi: 10.3389/fimmu.2013.00076.: 76.
43. VandenBussche CJ, Dakshanamurthy S, Posch PE, Hurley CK (2006) A single polymorphism disrupts the killer Ig-like receptor 2DL2/2DL3 D1 domain. Journal of Immunology 177: 5347-5357. (Pubitemid 44527607)
44. Ahlenstiel G, Martin MP, Gao X, Carrington M, Rehermann B (2008) Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. Journal of Clinical Investigation 118: 1017-1026. (Pubitemid 351364609)
45. Kulkarni S, Martin MP, Carrington M (2008) The Yin and Yang of HLA and KIR in human disease. Semin Immunol 20: 343-352.
46. Moretta L, Moretta A (2004) Killer immunoglobulin-like receptors. Current Opinion in Immunology 16: 626-633. (Pubitemid 39165891)
47. Kärre K (2002) A perfect mismatch. Science 295: 2029-2031.
48. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, et al. (2009) Antileukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 113: 3119-3129.
49. Karabon L, Jedynak A, Giebel S, Wolowiec D, Kielbinski M, et al. (2011) KIR/ HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens 78: 129-138.
50. Chan WK, Kung SM, Li Y, Zalevsky J, Schell S, et al. (2012) Antibodydependent cell-mediated cytotoxicity overcomes NK cell resistance in MLLrearranged leukemia expressing inhibitory KIR ligands but not activating ligands. Clin Cancer Res 18: 6296-6305.
51. Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, et al. (2009) KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 15: 7330-7334.
52. Formica V, Cereda V, di Bari MG, Grenga I, Tesauro M, et al. (2013) Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). Med Oncol 30: 743-0743.
53. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73.
54. Kasajima A, Sers C, Sasano H, Johrens K, Stenzinger A, et al. (2010) Downregulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum Pathol 41: 1758-1769.
55. Simpson JA, Al Attar A, Watson NF, Scholefield JH, Ilyas M, et al. (2010) Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 59: 926-933.
56. Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, et al. (2007) High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 67: 4725-4731. (Pubitemid 46910179)
57. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, et al. (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305: 872-874. (Pubitemid 39038423)
58. Brackenridge S, Evans EJ, Toebes M, Goonetilleke N, Liu MK, et al. (2011) An early HIV mutation within an HLA-B*57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1. J Virol 85: 5415-5422.
59. Fadda L, O'Connor GM, Kumar S, Piechocka-Trocha A, Gardiner CM, et al. (2011) Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules. J Virol 85: 5970-5974.
60. Liberatore C, Capanni M, Albi N, Volpi I, Urbani E, et al. (1999) Natural killer cell-mediated lysis of autologous cells modified by gene therapy. J Exp Med 189: 1855-1862. (Pubitemid 29295884)
61. Luo L, Du Z, Sharma SK, Cullen R, Spellman S, et al. (2007) Chainterminating natural mutations affect the function of activating KIR receptors 3DS1 and 2DS3. Immunogenetics 59: 779-792. (Pubitemid 47594099)
62. Stewart-Jones GB, di Gleria K, Kollnberger S, McMichael AJ, Jones EY, et al. (2005) Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705. Eur J Immunol 35: 341-351. (Pubitemid 40331309)
63. Stewart CA, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, et al. (2005) Recognition of peptide-MHC class I complexes by activating killer immuno-globulin- like receptors. Proc Natl Acad Sci U S A 102: 13224-13229. (Pubitemid 41325005)
64. Colantonio AD, Bimber BN, Neidermyer J, Reeves RK, Alter G, et al. (2011) KIR polymorphisms modulate peptide-dependent binding to an MHC class I ligand with a Bw6 motif. PLoS Pathog 7.
65. Alter G, Rihn S, Walter K, Nolting A, Martin M, et al. (2009) HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. Journal of Virology 83: 6798-6805.
66. Parsons MS, Zipperlen K, Gallant M, Grant M (2010) Killer cell immunoglob-ulin- like receptor 3DL1 licenses CD16-mediated effector functions of natural killer cells. J Leukoc Biol 88: 905-912.
67. Cariani E, Pilli M, Zerbini A, Rota C, Olivani A, et al. (2013) HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus-Related Hepatocellular Carcinoma. Clin Cancer Res 19: 5465-5473.
68. Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, et al. (2010) Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 138: 1536-1545.
69. Altfeld M, Goulder P (2007) 'Unleashed' natural killers hinder HIV. Nature Genetics 39: 708-710. (Pubitemid 46848581)
70. Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, et al. (2008) HLA alleles determine differences in human natural killer cell responsiveness and potency. Proceedings of the National Academy of Sciences of the United States of America 105: 3053-3058. (Pubitemid 351723666)
71. O'Connor GM, McVicar D (2013) The Yin-Yang of KIR3DL1/S1: Molecular Mechanisms and Cellular Function. Crit Rev Immunol 33: 203-218.
72. Kocian P, Sedivcova M, Drgac J, Cerna K, Hoch J, et al. (2011) Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence. Hum Immunol 72: 1022-1028.
73. Kocian P, Sedivcova M, Drgac J, Cerna K, Hoch J, et al. (2011) Tumorinfiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence. Hum Immunol 72: 1022-1028.
74. Bauer K, Nelius N, Reuschenbach M, Koch M, Weitz J, et al. (2013) T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer. Cancer Immunol Immunother 62: 27-37.